Search research articles
Contact Us
Filters
Showing results (201-210 of 327) with videos related to
Page
of 33
Sort By:
Plos One
|
July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Charles Marusak, Varsha Thakur, Yuan Li, et al.
JAMA Oncology
|
March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
J Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Oncoimmunology
|
February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
J Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2023
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Meghan E Sise, Qiyu Wang, Harish Seethapathy, et al.
Immunotherapy Advances
|
September 20, 2021
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
Zsofia D Drobni, Sean P Murphy, Raza M Alvi, et al.
Journal of the National Cancer Institute
|
October 27, 2015
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Priscilla K Brastianos, Ganesh M Shankar, Corey M Gill, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Page
of 33
Search research articles
Search
Showing results (201-210 of 327) with videos related to
Sort By:
Page
of 33
Plos One
|
July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Charles Marusak, Varsha Thakur, Yuan Li, et al.
JAMA Oncology
|
March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
J Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Oncoimmunology
|
February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
J Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2023
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Meghan E Sise, Qiyu Wang, Harish Seethapathy, et al.
Immunotherapy Advances
|
September 20, 2021
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
Zsofia D Drobni, Sean P Murphy, Raza M Alvi, et al.
Journal of the National Cancer Institute
|
October 27, 2015
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Priscilla K Brastianos, Ganesh M Shankar, Corey M Gill, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Page
of 33